For example, an early phase I clinical trial evaluating the same mRNA-transfected anti-c-Met CAR T-cells for breast cancer and melanoma patients planned to administer up to six doses of 1 × 108 modified T-cells over a short two-week period; however, this study was unfortunately terminated due to a halt in funding (NCT03060356). This evidence concerns the gene MET and breast carcinoma.